Benzinga · Aug 12, 2026
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
AT
NASDAQ · ATAI
Atai Beckley N.V
Healthcare · Medical - Pharmaceuticals
$7.38
Down-$0.04 (-0.54%)
Updated Aug 22, 2026, 3:46 AM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.71M
- P/E ratio
- -5.12
- Dividend yield
- 0.00%
- 52-week range
- $3.27 – $7.45
- Volume
- 4.31M
- Avg. volume
- 3.82M
Price performance
ATAI price history
1M range · 21 trading sessions · Daily adjusted prices
ATAI closed at $7.38 after 21 trading sessions, up 2.79% for the selected period.
- Last close
- $7.38
- Period change
- +2.79%
- Period low
- $7.17
- Period high
- $7.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $7.41 | $7.45 | $7.38 | $7.38 | 4.31M |
| Aug 20, 2026 | $7.38 | $7.45 | $7.35 | $7.42 | 9.22M |
| Aug 19, 2026 | $7.28 | $7.37 | $7.27 | $7.36 | 9.14M |
| Aug 18, 2026 | $7.25 | $7.325 | $7.24 | $7.29 | 10.49M |
| Aug 17, 2026 | $7.245 | $7.25 | $7.24 | $7.24 | 7.61M |
| Aug 14, 2026 | $7.24 | $7.28 | $7.23 | $7.26 | 6.1M |
| Aug 13, 2026 | $7.22 | $7.25 | $7.22 | $7.25 | 4.1M |
| Aug 12, 2026 | $7.22 | $7.23 | $7.22 | $7.23 | 3.87M |
| Aug 11, 2026 | $7.24 | $7.26 | $7.21 | $7.21 | 3.67M |
| Aug 10, 2026 | $7.22 | $7.26 | $7.22 | $7.25 | 3.45M |
| Aug 7, 2026 | $7.20 | $7.25 | $7.20 | $7.25 | 6.41M |
| Aug 6, 2026 | $7.20 | $7.22 | $7.18 | $7.18 | 4.42M |
| Aug 5, 2026 | $7.18 | $7.22 | $7.17 | $7.22 | 9.55M |
| Aug 4, 2026 | $7.17 | $7.18 | $7.16 | $7.18 | 6.32M |
| Aug 3, 2026 | $7.18 | $7.19 | $7.16 | $7.18 | 14.78M |
| Jul 31, 2026 | $7.19 | $7.21 | $7.18 | $7.18 | 8.92M |
| Jul 30, 2026 | $7.175 | $7.21 | $7.17 | $7.18 | 14.88M |
| Jul 29, 2026 | $7.165 | $7.19 | $7.16 | $7.18 | 18.61M |
| Jul 28, 2026 | $7.17 | $7.20 | $7.15 | $7.18 | 17.24M |
| Jul 27, 2026 | $7.17 | $7.195 | $7.16 | $7.17 | 9.63M |
| Jul 24, 2026 | $7.17 | $7.19 | $7.1607 | $7.18 | 6.97M |
Latest ATAI news
The latest Smart Investors Daily articles mentioning ATAI.
Stock researchCompany · Overview
ATAI research
Overview
Company profile and research snapshot.
Company profile
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.00
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Deutsche Bank | Hold | — |
| Jul 20, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 17, 2026 | Jones Trading | Hold | — |
| Jul 17, 2026 | Jefferies | Hold | — |
| Jul 16, 2026 | Maxim Group | Hold | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
Benzinga · Aug 12, 2026
Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8
Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.
Yahoo · Aug 7, 2026
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
